dc.contributor.author | Younes, Nadin | |
dc.contributor.author | Al-Sadeq, Duaa W. | |
dc.contributor.author | Shurrab, Farah M. | |
dc.contributor.author | Zedan, Hadeel T. | |
dc.contributor.author | Abou-Saleh, Haissam | |
dc.contributor.author | Abo-Halawa, Bushra Y. | |
dc.contributor.author | AlHamaydeh, Fatima M. | |
dc.contributor.author | Elsharafi, Amira E. | |
dc.contributor.author | Daas, Hanin I. | |
dc.contributor.author | Thomas, Swapna | |
dc.contributor.author | Aboalmaaly, Sahar | |
dc.contributor.author | Al Farsi, Afra | |
dc.contributor.author | Al-Buainain, Reeham | |
dc.contributor.author | Ataelmannan, Samar | |
dc.contributor.author | Paul, Jiji | |
dc.contributor.author | Al Saadi, Amana Salih | |
dc.contributor.author | Yassine, Hadi M. | |
dc.contributor.author | Majdalawieh, Amin | |
dc.contributor.author | Ismail, Ahmed | |
dc.contributor.author | Abu-Raddad, Laith J. | |
dc.contributor.author | Nasrallah, Gheyath K. | |
dc.date.accessioned | 2022-10-24T05:15:45Z | |
dc.date.available | 2022-10-24T05:15:45Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Younes, N.; Al-Sadeq, D.W.; Shurrab, F.M.; Zedan, H.T.; Abou-Saleh, H.; Abo-Halawa, B.Y.; AlHamaydeh, F.M.; Elsharafi, A.E.; Daas, H.I.; Thomas, S.; et al. Validation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees. Vaccines 2022, 10, 1318. https://doi.org/10.3390/vaccines10081318 | en_US |
dc.identifier.issn | 2076-393X | |
dc.identifier.uri | http://hdl.handle.net/11073/25040 | |
dc.description.abstract | Background: Limited commercial LFA assays are available to provide a reliable quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: This study aimed to evaluate the performance of the fluorescence LFA FinecareTM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113) against the following reference methods: (i) the FDA-approved GenScript surrogate virus-neutralizing assay (sVNT); and (ii) three highly performing automated immunoassays: BioMérieux VIDAS®3, Ortho VITROS®, and Mindray CL-900i®. Methods: Plasma from 488 vaccinees was tested by all aforementioned assays. Fingerstick whole-blood samples from 156 vaccinees were also tested by FinecareTM. Results and conclusions: FinecareTM showed 100% specificity, as none of the pre-pandemic samples tested positive. Equivalent FinecareTM results were observed among the samples taken from fingerstick or plasma (Pearson correlation r = 0.9, p < 0.0001), suggesting that fingerstick samples are sufficient to quantitate the S-RBD BAU/mL. A moderate correlation was observed between FinecareTM and sVNT (r = 0.5, p < 0.0001), indicating that FinecareTM can be used for rapid prediction of the neutralizing antibody (nAb) post-vaccination. FinecareTM BAU results showed strong correlation with VIDAS®3 (r = 0.6, p < 0.0001) and moderate correlation with VITROS® (r = 0.5, p < 0.0001) and CL-900i® (r = 0.4, p < 0.0001), suggesting that FinecareTM can be used as a surrogate for the advanced automated assays to measure S-RBD BAU/mL. | en_US |
dc.description.sponsorship | Qatar National Research Fund | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | MDPI | en_US |
dc.relation.uri | https://doi.org/10.3390/vaccines10081318 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | serology | en_US |
dc.subject | Lateral flow assay | en_US |
dc.subject | Automated immunoassay | en_US |
dc.subject | CLIA | en_US |
dc.subject | Neutralizing antibodies | en_US |
dc.subject | Surrogate virus neutralization test (sVNT) | en_US |
dc.title | Validation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees | en_US |
dc.type | Article | en_US |
dc.type | Peer-Reviewed | en_US |
dc.type | Published version | en_US |
dc.identifier.doi | 10.3390/vaccines10081318 | |